BIOGEN INC.

BIIB Health Care · Pharmaceuticals & Biotechnology

Latest period 2026-06-30 · 38 filings on record

Quarterly TTM Annual

8Q 3Y 5Y 10Y MAX

TTM 23-09 → TTM 26-06 12 TTM POINTS

SHOWING Trailing twelve months — each point sums the four quarters ending there.

Ranked against Health Care · 51 peers

Each grade is a single reported quarter's assessment, never an average — a card shows the grade at the newest quarter in view, so it follows the period and range controls above. Latest scored quarter: 2026-06-30.

Growth 15th pct

▼−5 over range · as of 2026-06-30

Revenue +3.4% YoY, earnings -84.6% YoY · sector avg 66

Quality 35th pct

▲+12 over range · as of 2026-06-30

3.6% net margin, 4% return on equity, 27% free-cash-flow margin, profitable in 7 of last 8 quarters · sector avg 45

Safety 43rd pct

▼−14 over range · as of 2026-06-30

Net debt 3.2x EBITDA, 1.9x current ratio · sector avg 59

OVERVIEWvs prior TTM Δ

Trailing twelve months · ending 2026-06-30 · green = improving · click a row to chart it

Revenue $10.0B +0.9% Gross margin 74.0% −1.5pp Operating margin — — Net margin 8.3% −5.5pp Net income $834.6M −39.2%

Debt / equity 0.43 +27.3%

EPS (diluted) — — EBITDA — —

Filings

TTM 23-09 → TTM 26-06 · following the period bar 3 match

ALL 10-K 10-Q Q1 Q2 Q3 FY CLEAR SORT NEWEST ↓

Filings by fiscal year and period
Year	Q1	Q2	Q3	FY
2026	10-Q Q1 2026	no filing	no filing	no filing
2025	10-Q Q1 2025	10-Q Q2 2025	10-Q Q3 2025	10-K FY 2025
2024	10-Q Q1 2024	10-Q Q2 2024	10-Q Q3 2024	10-K FY 2024
2023	10-Q Q1 2023	10-Q Q2 2023	10-Q Q3 2023	10-K FY 2023
2022	no filing	no filing	no filing	10-K FY 2022

10-Q Q2 2025 2025-07-31 Pro → 10-Q Q2 2024 2024-08-01 Pro → 10-Q Q2 2023 2023-07-25 Pro →

Filing-level fact detail is a Pro feature. The grades and figures above are free. See Pro plans

Trends

Trailing twelve months, rolling one quarter at a time

Revenue

Latest$10.0B vs prior TTM+0.9% Periods12

Revenue by period
Period	Period end	Revenue
TTM 23-09	2023-09-30	$10.0B
TTM 23-12	2023-12-31	$9.8B
TTM 24-03	2024-03-31	$9.7B
TTM 24-06	2024-06-30	$9.7B
TTM 24-09	2024-09-30	$9.6B
TTM 24-12	2024-12-31	$9.7B
TTM 25-03	2025-03-31	$9.8B
TTM 25-06	2025-06-30	$10.0B
TTM 25-09	2025-09-30	$10.1B
TTM 25-12	2025-12-31	$9.9B
TTM 26-03	2026-03-31	$9.9B
TTM 26-06	2026-06-30	$10.0B

Net income

Latest$834.6M vs prior TTM−39.2% Periods12

Net income by period
Period	Period end	Net income
TTM 23-09	2023-09-30	$1.5B
TTM 23-12	2023-12-31	$1.2B
TTM 24-03	2024-03-31	$1.2B
TTM 24-06	2024-06-30	$1.2B
TTM 24-09	2024-09-30	$1.6B
TTM 24-12	2024-12-31	$1.6B
TTM 25-03	2025-03-31	$1.5B
TTM 25-06	2025-06-30	$1.5B
TTM 25-09	2025-09-30	$1.6B
TTM 25-12	2025-12-31	$1.3B
TTM 26-03	2026-03-31	$1.4B
TTM 26-06	2026-06-30	$834.6M

ZOOM

TTM 09-12 TTM 26-06

Grade history

Point-in-time: each period shows the grade of the quarter it ends at — grades are never summed or averaged across a window.

Growth 15 Quality 35 Safety 43

Hover to read every grade at a period · shared with the trends chart · axis fixed 0–100

Grade history by period
Period	Period end	Growth	Quality	Safety
TTM 23-09	2023-09-30	20	23	57
TTM 23-12	2023-12-31	13	32	67
TTM 24-03	2024-03-31	29	46	52
TTM 24-06	2024-06-30	29	49	75
TTM 24-09	2024-09-30	48	51	31
TTM 24-12	2024-12-31	38	49	49
TTM 25-03	2025-03-31	38	46	50
TTM 25-06	2025-06-30	48	48	72
TTM 25-09	2025-09-30	44	56	74
TTM 25-12	2025-12-31	4	29	77
TTM 26-03	2026-03-31	41	44	77
TTM 26-06	2026-06-30	15	35	43